Breaking News

BioNxt Gains Trial Approval for Transdermal Rotigotine Patch for Parkinson’s

Completes the manufacture of all transdermal clinical samples based on the TDS platform technology developed by BioNxt's subsidiary, Vektor Pharma.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNxt Solutions Inc. has received government approval for to proceed with its comparative drug absorption study for the Company’s transdermal (TDS) Rotigotine patch for the treatment of Parkinson’s disease. The study is expected to begin in four to six weeks.   The Company previously received government approval for its planned human bioavailability study to be carried out by a qualified European contract research organization. The comparative study is designed to assess the relat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters